Session » Epidemiology & Public Health Poster III: Inflammatory Rheumatic Disease

Date: Sunday, November 8, 2020

Time: 9:00AM-11:00AM

Meeting: ACR Convergence 2020

9:00AM-11:00AM: Abstract Number: 1016

Annual Cardiac or Orthopedic Procedure Volume in Gout versus Rheumatoid Arthritis: A National Time-trends Study

9:00AM-11:00AM: Abstract Number: 1008

Assessing Improved Risk Prediction of Seropositive Rheumatoid Arthritis by Environmental, Genetic, and Preclinical Plasma Metabolite Factors

9:00AM-11:00AM: Abstract Number: 1007

Atopic Dermatitis and Risk of Incident Rheumatoid Arthritis: A Systematic Review and Meta-analysis

9:00AM-11:00AM: Abstract Number: 1029

Clinical Characteristics of Patients with Axial Spondyloarthritis in China: Results from the ChinaAS Registry

9:00AM-11:00AM: Abstract Number: 1022

Declining In-hospital Mortality Gap in Lupus Compared to Non-lupus Hospitalizations: A National Study

9:00AM-11:00AM: Abstract Number: 1014

Disease Modifying Anti-rheumatic Drugs, Biologics and Corticosteroid Use in Older Patients with Rheumatoid Arthritis over 20 Years

9:00AM-11:00AM: Abstract Number: 1011

Effectiveness, Safety and Quality of Life with Tofacitinib Treatment in Adult Patients with Rheumatoid Arthritis Under Routine Clinical Care: First Interim Results from a German Non-Interventional, Prospective, Multi-Center Study

9:00AM-11:00AM: Abstract Number: 1032

Epidemiology and Geographic Evaluation of ANCA-associated Vasculitis (AAV) at a Rural Academic Health Center Utilizing an Electronic Health Record (EHR)

9:00AM-11:00AM: Abstract Number: 1023

Epidemiology and Sociodemographic Distribution of Upper Gastrointestinal Bleeding Among Medicaid Beneficiaries with Systemic Lupus Erythematosus

9:00AM-11:00AM: Abstract Number: 1010

Infection and Malignancy Outcomes in Patients with RA Treated with Abatacept: Results from a Multinational Surveillance Study

9:00AM-11:00AM: Abstract Number: 1003

Long-term Weight Changes and Risk of Rheumatoid Arthritis Among Women in a Prospective Cohort: A Marginal Structural Model Approach

9:00AM-11:00AM: Abstract Number: 1009

Missing Data and Multiple Imputation in Rheumatoid Arthritis Registries Using Sequential Random Forest Method

9:00AM-11:00AM: Abstract Number: 1013

National Burden of RA in Canada 1990-2017: Findings from the Global Burden of Disease Study 2017

9:00AM-11:00AM: Abstract Number: 1021

Organ Damage in Systemic Lupus Erythematosus Is Attributable More to Comorbidity (Hypertension) and Less to Socioeconomic Status

9:00AM-11:00AM: Abstract Number: 1019

Outdoor Air Pollution and Systemic Lupus Erythematosus

9:00AM-11:00AM: Abstract Number: 1030

Pain Medication Use Among Ankylosing Spondylitis and Psoriatic Arthritis Patients Before and After Initiation of Biologic Therapy

9:00AM-11:00AM: Abstract Number: 1000

Passive Smoking Throughout the Life Course and the Risk of Incident Rheumatoid Arthritis in Adulthood Among Women

9:00AM-11:00AM: Abstract Number: 1006

Post-menopausal Rheumatoid Arthritis Is Inversely Associated with Lifetime High Level of Estrogen Exposure in the French E3N Cohort

9:00AM-11:00AM: Abstract Number: 1025

Prevalence Estimates for Systemic Lupus Erythematosus over Four Decades

9:00AM-11:00AM: Abstract Number: 1028

Probabilistic Linkage of a Cohort of Individuals with Symptoms Suggestive of Early Spondyloarthritis and the French National Healthcare Database

9:00AM-11:00AM: Abstract Number: 1002

Prostate Cancer Risk Is Not Increased in Rheumatoid Arthritis After Accounting for Retention in a Health Care System

9:00AM-11:00AM: Abstract Number: 1017

Racial and Ethnic Disparities in the Risk of Preterm Birth Among Women with Systemic Lupus Erythematosus or Rheumatoid Arthritis with Varying Reference Groups

9:00AM-11:00AM: Abstract Number: 1031

Real World Treatment Patterns Among Patients with Psoriatic Arthritis Treated with Ixekizumab

9:00AM-11:00AM: Abstract Number: 1020

Relationship Between Skin-related Quality of Life, Psychosocial Stress, and Race in Cutaneous Lupus Erythematosus

9:00AM-11:00AM: Abstract Number: 1001

Risk of Malignant Melanoma and Nonmelanoma Skin Cancer in Rheumatoid Arthritis Patients Initiating Methotrexate versus Hydroxychloroquine

9:00AM-11:00AM: Abstract Number: 1005

Risk of Non-vertebral Fractures Among Rheumatoid Arthritis Patients Treated with Biologic or Targeted-Synthetic DMARDs: A Multi-Database Comparative Safety Study

9:00AM-11:00AM: Abstract Number: 1018

Seasonal Variation in the Treat-to-Target Rate of Rheumatoid Arthritis (RA) and Systemic Lupus Erythematosus (SLE): A Cohort Study on Self-reported Data from Smart System of Disease Management (SSDM)

9:00AM-11:00AM: Abstract Number: 1012

The Global Prevalence of Rheumatoid Arthritis: A Meta-Analysis

9:00AM-11:00AM: Abstract Number: 1004

The Incidence, Mortality, and Economic Burden of Potentially Preventable Infections in Rheumatoid Arthritis Patients

9:00AM-11:00AM: Abstract Number: 1026

The Incidence, Mortality, and Economic Burden of Potentially Preventable Infections in Systemic Lupus Erythematosus Patients

9:00AM-11:00AM: Abstract Number: 1027

The National Prevalence of Clinically Diagnosed Psoriatic Arthritis in Sweden 2017

9:00AM-11:00AM: Abstract Number: 1015

The Prevalence and Risk Factors for Liver Fibrosis Among Rheumatoid Arthritis (RA) Patients on Disease-Modifying Anti-rheumatic Drugs (DMARDs)

9:00AM-11:00AM: Abstract Number: 1024

Time Trends in the Incidence of Systemic Lupus Erythematosus: A 40-Year Study

« View all sessions from this meeting

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].